Renin-angiotensin system antagonists, glomerular filtration rate and blood pressure

Main Article Content

D.D. Ivanov


The article deals with the Modern data on the influence of renin-angiotensin system blockers on the glomerular filtration rate, the level of arterial pressure and the outcome of chronic kidney disease. The strategy of  rennin-angiotensine blockade is offered to be changed depending on the criteria va­lues of glomerular filtration rate: a combination of inhibitors of angiotensin-converting enzyme + angiotensin receptors blo­ckers, monotherapy and drug withdrawal in glomerular filtration rate under 15–30 ml/min/m2. The formula BRIMONEL for treatment of chronic kidney disease is given.

Article Details

How to Cite
Ivanov, D. “Renin-Angiotensin System Antagonists, Glomerular Filtration Rate and Blood Pressure”. KIDNEYS, vol. 7, no. 1, Feb. 2018, pp. 6-10, doi:10.22141/2307-1257.7.1.2018.122214.
Guest Articles


Vejakama P, Ingsathi A, McKay GJ, et al. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients. BMC Nephrol. 2017 Nov 29;18(1):342. doi: 10.1186/s12882-017-0753-9.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. 2013;3:1-150.

National Institute for Health and Care Excellence (NICE). Chronic kidney disease in adults: assessment and management. Clinical guideline. Available from: Accessed: July 2014.

Ivanov DD, Kushnirenko SV. BRA II1+ ACEI vs BRA II1+ ACEI+ COX-2 inhibitor vs BRA II1+ ACEI+ moxonidin in patients with diabetic nephropathy (DN). In: Proceeding of the XLII ERAEDTA Congress. 2005, June 4-7; Istanbul, Turkey. Nephrol Dial Transplant. 2005;20 suppl 5:V240-V240.

Maione A, Navaneethan SD, Graziano G, et al. Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials. Nephrol Dial Transplant. 2011 Sep;26(9):2827-47. doi: 10.1093/ndt/gfq792.

Schmidt M, Mansfield KE, Bhaskaran K, et al. Serum Creatinine Elevation After Renin-angiotensin System Blockade and Long Term Cardiorenal Risks. BMJ. 2017 Mar 9;356:j791. doi: 10.1136/bmj.j791.

Lin CC, Wu YT, Yang WC, et al. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with reninangiotensinsystem blockade. PLoS One. 2017 Dec 7;12(12):e0189126. doi: 10.1371/journal.pone.0189126.

ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317.

Introduction: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S1-S2. doi: 10.2337/dc18-Sint01.

Ivanov DD. When should we start using angiotensin converting enzyme inhibitors/angiotensin receptor blockers in diabetic kidney disease? Pochki. 2017; 6(1):31-35. doi: 10.22141/2307-1257.6.1.2017.93781.

Ivanov DD. Next step in chronic kidney disease therapy. Pochki. 2016; 5(2):10-13. doi: 10.22141/2307-1257.

Miura S, Karnik SS, Saku K. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects. J Renin Angiotensin Aldosterone Syst. 2011 Mar;12(1):1-7. doi: 10.1177/1470320310370852.

Ahmed AK, Kamath NS, El Kossi M, El Nahas AM. The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease. Nephrol Dial Transplant. 2010 Dec;25(12):3977-82. doi: 10.1093/ndt/gfp511.

Gant CM, Laverman GD, Vogt L, et al. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol. 2017 Dec 20;18(1):370. doi: 10.1186/s12882-017-0789-x.

Georgianos PI, Agarwal R. Revisiting RAAS blockade in CKD with newer potassium-binding drugs. Kidney Int. 2017 Dec 21. pii: S0085-2538(17)30808-6. doi: 10.1016/j.kint.2017.08.038.

Böhm M, Schumacher H, Teo KK, et al. Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. Lancet. 2017 Jun 3;389(10085):2226-2237. doi: 10.1016/S0140-6736(17)30754-7.

SPRINT Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939.

Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017 Nov 13. pii: HYP.0000000000000065. doi: 10.1161/HYP.0000000000000065.

Basy S, Sussman JB, Hayward RA. Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment: A Modeling Study of Randomized Clinical Trials. Ann Intern Med. 2017 Mar 7;166(5):354-360. doi: 10.7326/M16-1756.

Mark PB. Strategies to manage cardiovascular risk in chronic kidney disease. Nephrol Dial Transplant. 2018 Jan 1;33(1):23-25. doi: 10.1093/ndt/gfx329.